Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis


Abstract
This study reports on a group of 20 patients with an initial diagnosis of primary biliary cirrhosis (PBC) whose serum tested negative for antimitochondrial antibodies by immunofluorescence. All had a clinical history compatible with primary biliary cirrhosis, and results of biochemical, histological, and radiological investigations were consistent with this diagnosis despite the absence of antimitochondrial antibodies by immunofluorescence. For comparison, these patients were matched for sex and serum bilirubin with 20 antimitochondrial antibody positive (>1:160) and histologically confirmed primary biliary cirrhosis patients who served as controls. Serum samples from both groups were retested blindly for antimitochondrial antibodies using immunoblotting and for antibodies to the major M2 mitochondrial autoantigens by enzyme linked immunosorbent assay (ELISA). Three antimitochondrial antibody immunofluorescence negative patients had antimitochondrial antibodies by immunoblotting and ELISA; the remaining 17 patients were confirmed negative by all methods. The antimitochondrial antibody immunofluorescence positive controls were verified by immunoblotting or ELISA, or both. All 17 patients negative for antimitochondrial antibodies had antinuclear antibodies, often in high titres, compared with 3/17 of the antimitochondrial antibody positive controls (p = 0.001). Additionally, the antimitochondrial antibody negative group also had significantly higher smooth muscle antibody titres (p = 0.03) and lower serum IgM (p = 0.01) and aspartate aminotransferase (p = 0.03) activities than the antimitochondrial antibody positive controls. Analysis of clinical findings, histological tests, serum bilirubin, alkaline phosphatase, alanine aminotransferase, and IgG, disclosed no significant differences between the two groups. This paper describes a group of patients with the clinical and histological features of PBC but who did not fulfil the usual criteria necessary to make this diagnosis. Because they also have very high titres of antinuclear antibodies, smooth muscle antibodies, and comparatively low IgM and aspartate aminotransferase activities, we believe they are distinct from PBC and have a syndrome of autoimmune cholangitis. (Gut 1994; 35: 260–265)

Primary biliary cirrhosis (PBC) is a chronic progressive liver disease of unknown cause. A positive diagnosis in patients who may or may not be symptomatic, usually requires the combination of an increase in serum alkaline phosphatase and immunoglobulin M (IgM), together with serum antimitochondrial antibodies (AMA) and histological evidence of bile duct injury and portal inflammation.

Most patients with PBC (greater than 80%) have AMA when serum samples are tested with the immunofluorescence technique (AMA-IF). In one series of 218 patients, nine were AMA-IF negative and seven of these were subsequently found to be AMA-IF positive when additional serum specimens were examined suggesting that less than 1% of PBC patients were negative for AMA-IF in this large study. The identification and purification of the major mitochondrial autoantigens has permitted immunoblot assays to be developed that are more sensitive than immunofluorescence techniques for the detection of AMA.

In this study we report the clinical, serological, and histological features of patients initially thought to have PBC by all the accepted criteria except they proved to be AMA-IF negative. Our findings show that patients with AMA-negative PBC may have a syndrome immunologically distinct from AMA-positive PBC.

Methods

PATIENTS
The subjects in this study are 20 Canadian patients (primarily from southern Ontario) with an initial clinical diagnosis of PBC who were referred for possible inclusion into a therapeutic trial of ursodeoxycholic acid, but were ineligible because their serum samples were AMA-IF negative and thus they were not treated. We selected a comparison group of 20 AMA-IF positive (titre >1:160) PBC patients who were referred to the same trial and used their serum (before entering the trial) for this study. These controls were selected because they matched the study subjects for sex and serum bilirubin at the time of referral. Testing for serum antimitochondrial antibodies by the methods described below, was then performed on the index patients and controls. The group of patients who were confirmed AMA negative by all testing methods (referred to as AMA-all negative) were then compared with the matched AMA positive (AMA-all positive) controls for the presence of other non-organ specific antibodies, clinical features, serum liver biochemistry, and percu-
Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis

SEROLOGICAL TESTS
Serum was tested by indirect immunofluorescence for the presence of antimitochondrial (AMA-IF), antinuclear, and smooth muscle antibodies. Frozen sections of rat kidney and stomach as well as a Hep-2 cell line (Kallestad Diagnostics, Chaska MN) were used as substrate. Serum was screened at dilution of 1/20 and 1/40 and further dilutions were tested when indicated. The conjugate used was fluorescein conjugated rabbit anti-human IgA, IgG, IgM, kappa and lambda (Dakopatts, Glostrup Denmark), which had a protein concentration of 4-2 g/l and a fluorescein/protein molar ratio of 2-3. The dilution of the conjugate used was 1/160 in phosphate buffered saline as determined by chessboard titration. Each section and tissue culture was examined by two pathologists using a Leitz Orthoplan fluorescent microscope with a Ploemopak 2 vertical illuminator equipped with water immersion objectives.

Serum samples were tested for AMA by immunoblotting. For this assay, pyruvate dehydrogenase complex, 2-oxo-glutarate dehydrogenase complex was purified from bovine heart,2 and branched chain 2-oxo acid dehydrogenase complex was purified from rat liver (gift of Dr Y Shimomura, University of Nagoya, Japan).3 Western immunoblotting against these three complexes was performed as previously described4 at a serum dilution of 1:100 and 1:1000 and using 2 µg of each complex per lane. Reactivity was visualised using peroxidase conjugated IgG and IgM specific secondary antibodies (Sigma Chemical Co, St Louis, Mo) with 4-chloro-1-naphthol as substrate.3 Samples were also tested for AMA by an ELISA using purified mitochondrial antigens as previously described.1 The E2 component together with protein X of the pyruvate dehydrogenase complex was obtained by resolution of the complex using gel filtration chromatography in the presence of 1 M NaCl.

The liver specimens were fixed in buffered formalin, embedded in paraffin wax, and sections stained with haematoxylin and eosin, Masson's trichrome, orcein, PAS after diastase, and by the Prussian blue method. Slides were reviewed independently by two pathologists (IRW and PJS) who had no knowledge of the AMA results; for each biopsy specimen a histological diagnosis was assigned as definite PBC, probable PBC, non-specific but possible PBC, or other diagnosis. One pathologist (IRW), graded the histological parameters of fibrosis, inflammation, duct paucity, and duct necrosis using a scale of 0 to 3 (none, mild, moderate, and severe). Granulomas were noted as present or absent.

STATISTICAL ANALYSIS
The differences between the AMA negative patients and their AMA positive controls were compared using the Wilcoxon rank sign test for various clinical and histological features and the serum measurements of alkaline phosphatase, aminotransferases, antinuclear titres, smooth muscle antibodies titres, IgM, and IgG.

Results
Seventeen of 20 (85%) AMA-IF negative patients were confirmed to be also negative for AMA by ELISA for E2/X and immunoblotting (will be referred to as AMA-all negative) (Table I). Three of 20 AMA-IF negative patients (15%) were found to have antibodies to pyruvate dehydrogenase complex E2/protein X by ELISA; testing with immunoblotting verified IgM and IgG antibodies to pyruvate dehydrogenase complex in two of these patients and branch chain 2-oxo acid dehydrogenase complex antibodies in the other. All 20 AMA-IF positive control patients were confirmed AMA positive for pyruvate dehydrogenase complex E2/X by ELISA (AMA-all positive).

Recognising that the detection of AMA-IF increases as patients are retested over time,1 we performed at least three immunofluorescence tests on separate samples in the 20 AMA-IF negative patients; 19 continued to be negative over several years. The only exception was one patient initially testing AMA-IF negative who became AMA-IF positive after two years. On retesting the initial serum of this patient, it was positive by ELISA and immunoblotting. Two other AMA-IF negative but ELISA positive patients who have been followed up for five and three years respectively continue to test AMA-IF negative.

Further investigations showed that all of the 17 AMA-all negative patients were antinuclear antibody positive; eight with a titre of 1:160-1:1280, eight at 1:40-1:80, and one at 1:20 (Table II). Three of 17 AMA-all negative patients were positive for antinuclear antibodies only on rat kidney substrate while the remaining 14 were positive in both rat kidney and Hep 2 cells. This was considerably different from the antinuclear antibody titres in the 17 AMA-all positive patients (p=0.001), all but three of whom were antinuclear antibody negative (titres <1:20). No consistent immunofluorescence staining pattern was seen in either group. Smooth muscle antibody was also more prevalent in the AMA negative group (30 ± 5%, p=0.03).

Eighty two per cent (14/17) of the AMA-all negative patients were female. All 17 had an abnormal alkaline phosphatase, four an abnormal bilirubin, and 10 an increased IgM value. Cholangiography was attempted in all the AMA-all negative patients and was successful in 14, all

![Table 1: Summary of antimitochondrial antibody (AMA) investigations](image-url)
TABLE II  Summary of antinuclear antibody (ANA) titres, immunofluorescence patterns, and smooth muscle antibody (SMA) titres

<table>
<thead>
<tr>
<th>ANA titres</th>
<th>AMA-all negative patients (n=17)</th>
<th>AMA-all positive patients (n=17)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:100-1:1280</td>
<td>8</td>
<td>2</td>
</tr>
<tr>
<td>1:40-1:80</td>
<td>8</td>
<td>0</td>
</tr>
<tr>
<td>1:20</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Total</td>
<td>17*</td>
<td>3</td>
</tr>
</tbody>
</table>

Patterns:
- Homogeneous: 6 0
- Speckled: 2 1
- Anti-centromere: 3 0
- Multiple nuclear dot: 2 1
- Rim: 1 0
- Indeterminate: 3 0

SMA titres:
- 1:20-1:40: 4 1
- 1:80-1:160: 3 0
- Total: 7* 1

*p=0.001 for ANA, p=0.03 for SMA.

TABLE III  Summary of clinical parameters

<table>
<thead>
<tr>
<th>Parameters at time of referral</th>
<th>AMA-IF negative patients (n=17)</th>
<th>AMA-IF positive patients (n=17)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female: male ratio</td>
<td>14:3</td>
<td>14:3</td>
</tr>
<tr>
<td>Age at diagnosis (mean, range)</td>
<td>51±1 (35-63)</td>
<td>55±0 (31-79)</td>
</tr>
<tr>
<td>Jeardice</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Fatigue</td>
<td>8</td>
<td>7</td>
</tr>
<tr>
<td>Pruritus</td>
<td>9</td>
<td>11</td>
</tr>
<tr>
<td>Xanthelasma</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Hypothyroidism</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Polyclathagias</td>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td>Sicca syndrome</td>
<td>3</td>
<td>7</td>
</tr>
<tr>
<td>CRST syndrome</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Raynus's phenomenon</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>Insulin dependent diabetes</td>
<td>2</td>
<td>1</td>
</tr>
</tbody>
</table>

*p>0.05 for all parameters

of whom had normal extrahepatic bile ducts. No patient had a history of diarrhoea, ulcerative colitis or spondylarthropathy. No patient had been treated with drugs known to cause bile duct paucity or with corticosteroids. After the diagnosis of AMA-IF negative PBC, no patient was treated with any drugs except cholestryamine for pruritus.

Comparison of the clinical findings showed no significant difference between the AMA-all negative and AMA-all positive patients with respect to signs, symptoms, and associated autoimmune phenomena at the time of diagnosis (Table III). Similarly, serum IgG, alkaline phosphatase, and alanine aminotransferase activities at the time of referral were not significantly different (Table IV). The serum IgM and aspartate aminotransferase, however, were significantly lower in the AMA-IF negative group (p=0.01 and p=0.03 respectively).

The mean follow up time in the AMA-all negative and positive patients was 4.8 ± 4.4 years respectively. One AMA-all negative patient received a liver transplant and another died of liver failure while two patients in the AMA-positive group received liver transplants. Nine AMA-all negative patients and 11 AMA-all positive patients had symptoms of pruritus, jaundice or xanthelasma at the time of diagnosis. A further three AMA-all negative patients and one AMA-all positive patient who were asymptomatic at diagnosis subsequently developed pruritus or xanthelasma, or both after the follow up period up to five years after diagnosis. Ten AMA-all negative and nine AMA-all positive patients had at least one associated autoimmune phenomenon at the time of diagnosis. One more AMA-all negative and three AMA-all positive patients subsequently developed a new associated autoimmune disease. Hence there were no clinical features that distinguished the two groups.

All 17 biopsy specimens from the AMA-all negative patients showed a portal inflammatory infiltration that was mixed with a predominance of lymphocytes and smaller numbers of plasma cells, eosinophils, and neutrophils. Within a given biopsy specimen the infiltrate often varied and tracts with active duct injury usually had more severe infiltration with lymphoid and granulocytic cells evenly represented (Fig 1). Nodular lymphoid aggregates without germinal centres were seen in one biopsy specimen. Mild parenchymal lymphoid infiltration was present in seven specimens, often associated with focal

TABLE IV  Summary of laboratory parameters

<table>
<thead>
<tr>
<th>Parameters at time of referral (normal range)</th>
<th>AMA-IF negative patients (n=17) (mean, median, range)</th>
<th>AMA-IF positive patients (n=17) (mean, median, range)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total bilirubin (&lt;20 µmol/l)</td>
<td>43 (12, 7-209)</td>
<td>38 (15, 7-239)</td>
</tr>
<tr>
<td>ALP (&lt;100 IU/l)</td>
<td>500 (129, 169-1252)</td>
<td>374 (350, 106-880)</td>
</tr>
<tr>
<td>AST (&lt;35 IU/l)</td>
<td>79 (63, 22-176)*</td>
<td>112 (90, 24-254)</td>
</tr>
<tr>
<td>ALT (&lt;40 IU/l)</td>
<td>94 (61, 20-216)</td>
<td>124 (101, 18-297)</td>
</tr>
<tr>
<td>IgM (5-15-6 g/l)</td>
<td>17-75 (15-9, 9-3-29-5)</td>
<td>16-8 (14-6, 9-36-1)</td>
</tr>
<tr>
<td>IgM (0-4-3-2 g/l)</td>
<td>5-6 (3.2-0.5-6.6)*</td>
<td>4-6 (4-9, 1.9-17-4)*</td>
</tr>
</tbody>
</table>

*p=0.01 for IgM, p=0.03 for AST, other parameters not significantly different. ALP=alkaline phosphatase; AST=aspartate aminotransferase; ALT=alanine aminotransferase.
Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis

Histological diagnosis:

<table>
<thead>
<tr>
<th></th>
<th>AMA-all negative patients (n=17)</th>
<th>AMA-all positive patients (n=17)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Definite or likely PBC</td>
<td>7</td>
<td>10</td>
</tr>
<tr>
<td>Non-specific, compatible with PBC</td>
<td>10</td>
<td>7</td>
</tr>
<tr>
<td>Other diagnosis</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Specific histological parameters:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duct necrosis (grade 2–3)</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Duct paucity (grade 2–3)</td>
<td>9</td>
<td>8</td>
</tr>
<tr>
<td>Portal inflammation (grade 2–3)*</td>
<td>7</td>
<td>14</td>
</tr>
<tr>
<td>Granulomata (present)</td>
<td>3</td>
<td>7</td>
</tr>
<tr>
<td>Fibrosis (grade 2–3)</td>
<td>8</td>
<td>7</td>
</tr>
</tbody>
</table>

*p=0.02 for portal inflammation; all other comparisons not significant.

PBC=primary biliary cirrhosis.

Discussion

We describe a group of 20 predominantly female patients, who have the clinical, biochemical, and histological appearance of PBC, but who did not have AMA by immunofluorescence despite repeated investigations during several years of follow up. Reports in published works suggest that 1–16% of PBC patients do not have AMA by immunofluorescence. Our group of 20 AMA-IF negative patients was initially identified from a cohort of 330 patients with PBC who were referred for a clinical trial. This apparent prevalence of 6%, however, may be falsely low, because we initially canvassed for patients who were AMA positive.

Application of the more sensitive and specific assays of immunoblotting and ELISA for detection of AMA in the 20 AMA-IF negative patients, confirmed that 17 (85%) of these patients are truly AMA negative.

The 17 AMA-all negative patients and their controls were comparable in all respects including clinical findings, prevalence of autoimmune diseases, serum bilirubin, alkaline phosphatase, alanine aminotransferase, and IgG values. Because these AMA-all negative patients, however, truly lack antimitochondrial antibodies and have a comparatively low IgM concentration, they do not fulfill the criteria generally used to make the diagnosis of classic PBC. Additionally, five significant differences were present in the AMA-all negative patients; they were more likely to have antinuclear antibodies (frequently in high titre), smooth muscle antibodies, a lower serum IgM concentration, lower serum aspartate aminotransferase concentration, and less portal inflammation in their liver biopsy specimens.

Patients with AMA-IF positive PBC have also been found to have antinuclear antibodies with a prevalence of 0 to 46%. Our AMA-all positive controls had a prevalence of 15%. This is appreciably different from the 100% prevalence found in our 17 AMA-all negative patients. A recent study in PBC examining antinuclear antibodies to a nuclear envelope protein, showed that the presence of this family of antibodies is not specific for a subset of patients with a particular pattern of clinical, biological or histological features.

Specific antinuclear antibody subtypes have been described in PBC, but none of these subtypes was overrepresented in our AMA-all negative cases. For example, antibodies with a nuclear rim pattern have been reported in about half of antinuclear positive PBC patients and in 3/4 AMA-IF negative PBC patients. We have not seen this pattern in AMA positive PBC patients and it was present in 1/17 AMA-all negative patients. Similarly, the multiple nuclear...
dot pattern seemed to be overrepresented in AMA-IF negative PBC in one study. We found this pattern in only two of 17 AMA-all negative patients.

The presence of antinuclear and antismooth muscle antibodies raises the question of autoimmune chronic active hepatitis in our AMA-all negative patients. We believe this is unlikely as the symptoms and clinical findings were typical of cholestasis not hepatitis, and their serum aminotransferase values were not in the hepatitic range. In fact, the aspartate aminotransferase was significantly lower in the AMA-all negative patients than in the PBC control group. Additionally, the AMA-all negative liver biopsy specimens did not have perportal inflammation and necrosis ('piecemeal necrosis'), but did have the histological features of duct injury and granulomas, which are not often seen in chronic active hepatitis.

The overlap syndrome of PBC and autoimmune chronic aggressive hepatitis was suggested by Kloppel et al. They described 27 AMA positive patients, 13 of whom had antibodies directed against the outer mitochondrial membrane. They frequently had positive antinuclear antibodies and had biopsy specimens that showed parenchymal injury and piecemeal necrosis. A similar AMA positive and antinuclear antibody positive patient has also been described who had features of both PBC and chronic active hepatitis on liver biopsy examination. Recently, there was a report of an AMA negative, antinuclear antibody and smooth muscle antibody positive woman with the clinical and pathological features of both autoimmune chronic aggressive hepatitis and PBC. Upon treatment with prednisone, her clinical course improved. The patients described in these publications were clearly very different from ours in that they were either AMA positive, or had high aminotransferases and liver biopsy specimens showing piecemeal necrosis and parenchymal injury, or all three.

Bile duct injury and loss has been reported in a variety of clinical settings in addition to PBC, including primary sclerosing cholangitis, graft versus host disease, graft rejection, and drug toxicity. An important paper by Ludwig et al has reported the existence of adult onset ductopenia in the absence of these conditions. There are approximately 13 patients reported to date with adult onset idiopathic ductopenia in the absence of AMA. Unlike our AMA-all negative population these patients were often men, did not have evidence of ulcerative colitis, did not have hepatic granulomas, and duct necrosis was usually not seen. No reference to the presence or absence of autoantibodies was made.

Brunner et al reported three AMA-IF negative women who had ductopenia with antinuclear in high titre. Histological examination showed a granuloma in one patient and duct necrosis in another, confirming a PBC like syndrome. After immunosuppressive treatment with prednisone and azathioprine, the liver enzymes improved and the term 'immunocholangitis' was applied to these patients. Available data suggest that these three patients had a similar disease pattern to our AMA negative patients. Our patients, however, have been treated with only palliative measures to date.

There is evidence suggesting that AMA in the form of autoantibodies against the pyruvate dehydrogenase-E2 may be the T-cell epitope, which may initiate the T-cell response leading to biliary epithelial damage. Monoclonal mouse antibodies, which react to PDH-E2 produce distinct intense activity when used to stain bile ducts in patients with PBC in contrast with bile duct specimens from patients with primary sclerosing cholangitis, and autoimmune chronic active hepatitis. Cloned T-cell lines have been generated from patients with PBC, but not from those with chronic aggressive hepatitis, which produce IL-2 specifically in response to PDH-E2. In contrast, our results suggest that the clinical and histological pattern typical of PBC is quite independent of any evidence of serum antibodies for AMA. This may signify that AMA play no part in the pathogenesis of PBC or that the clinical and histological features we would normally associate with AMA positive PBC are a non-specific response to an immune liver macrophage.

In conclusion, there are now several syndromes with features of apparent autoimmune liver injury including primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune chronic active hepatitis. Our 17 AMA-all negative patients were initially thought to have PBC based on their symptoms and histological tests. They did not have, however, the immune markers associated with PBC (AMA and raised IgM), two of four criteria commonly used to make the diagnosis of PBC. Instead they have antinuclear antibodies often at very high titres, smooth muscle antibodies, and comparatively low serum IgM and aspartate aminotransferase activities. We believe that these AMA-all negative patients have a form of autoimmune cholangitis distinct from that seen in AMA positive PBC and other autoimmune liver diseases, which may have a different pathogenesis. Further characterisation of the cause and pathogenesis of such patients will be necessary before this classification can be refined.

We thank Dr S P M Fussey for performing some of the immunoassays and J Mariano for conducting the immunofluorescence tests. We also thank referring physicians Dr C N Ghent, G Y Minuk, and R J Bailey for allowing us to study their patients and K Cauch and V Walker for their expert help in preparing this manuscript.

This work was presented at the AGA in San Francisco, USA May 1992 and IASL in Brightdon, UK June 1992. It was published in abstract form in Hepatology 1992; 16: 568. We are grateful to the Wellcome Trust for supporting this work with a project grant (JMP, SJY, MBF).

7 Van de Water J, Fremeau D, Davis P, Ansari A, Danner D,
Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis


Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis.


Gut 1994 35: 260-265
doi: 10.1136/gut.35.2.260

Updated information and services can be found at:
http://gut.bmj.com/content/35/2/260

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Pancreas and biliary tract (1949)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/